JOHANNESBURG (Reuters) - Shareholders of South Africa's Cipla Medpro overwhelmingly approved a $488 million takeover offer from India's Cipla Ltd on Wednesday, giving the Indian drugmaker a big presence in Africa's biggest economy.
There had been some concern the 4.5 billion rand deal - the biggest by an Indian firm in South Africa - could fall through after Cipla Medpro's top shareholder said the price undervalued the Cape Town-based company.
A total of 99.7 percent of shareholders voted in favour of the deal, Cipla Medpro said in a statement.
Cipla supplies the bulk of Cipla Medpro's drugs through a long-standing agreement but has never owned a stake in it.
Shares in Cipla Medpro rose 1.9 percent to 9.65 rand by 0948 GMT, below the 10 rand per share offer.
Black empowerment group Sweet Sensations, the top shareholder in Cipla Medpro with an 18 percent stake, said in March it would ask the Indian company to raise its offer, causing some concern the deal could be scuppered.
Cipla Medpro would be delisted from the JSE on 3 September
(Reporting by Tiisetso Motsoeneng; Editing by David Dolan)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
